Janeen Noel Doyle - Jun 2, 2025 Form 4 Insider Report for Janux Therapeutics, Inc. (JANX)

Role: Chief Corp. & Bus. Dev. Ofcr
Signature: /s/ James Pennington, Attorney-in-Fact
Stock symbol: JANX
Transactions as of: Jun 2, 2025
Transactions value $: $0
Form type: 4
Date filed: 6/4/2025, 08:00 PM
Previous filing: May 23, 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Doyle Janeen Noel	Chief Corp. & Bus. Dev. Ofcr	C/O JANUX THERAPEUTICS, INC., 10955 VISTA SORRENTO PARKWAY, SUITE 200, SAN DIEGO	/s/ James Pennington, Attorney-in-Fact	2025-06-04	0002069239

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	JANX	Common Stock	Award	$0	+44K		$0.00	44K	Jun 2, 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	JANX	Stock option (right to buy)	Award	$0	+154K		$0.00	154K	Jun 2, 2025	Common Stock	154K	$25.01	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on June 1, 2026.
F2	25% of the shares subject to the option vest on May 14, 2026 and the balance will vest in equal monthly installments thereafter over a three year period.